# R1 Clinical-Safety Review — desmoplastic_infantile_ganglioglioma

**Verdict: APPROVE**

Reviewer: stewardmd-clinical-safety-reviewer (R1, blocking gate)
Adversarial verdict file (.verdict.md): NOT PRESENT — no prior flagged issues to gate against.
Goldens changed: no (intended: n/a — narrative content only, no engine/rule change).

## 1. Safety
No unsafe, misleading, or absolute directive. Core claims (surgery-first for a WHO grade 1 infantile
glioneuronal tumour; GTR usually curative; radiotherapy avoided in infancy for neurocognitive/
developmental reasons; chemo reserved for progressive/incompletely resected disease; perioperative
attention to raised ICP/hydrocephalus) are consistent with standard paediatric neuro-oncology practice
and cannot cause harm if followed. Language is decision-support, not command ("treatment of first
choice", "would only be considered", "options move toward"). "Overwhelmingly benign" / "typically
curative" are accurate for DIG/DIA post-GTR, not an overstatement.

## 2. Grounding
Attribution is meticulous and exactly what R1 requires. The author acknowledges DeVita has no
DIG/DIA-specific section (grep-verified), uses only the general ganglioglioma section for the
principles it genuinely supports (surgery mainstay, STR-driven/limited RT role, reserved salvage
chemo, BRAF V600E as a diagnostic marker), and every infantile-specific or DIG-specific claim
(surgery-first extrapolation, ICP/hydrocephalus management, RT-avoidance in infancy, BRAF/MEK
targeted therapy) is explicitly relabelled as general oncology standard rather than mis-attributed
to DeVita. No fabricated or outdated regimen. No claim cites DeVita for something not in DeVita.

## 3. Dose-free
Confirmed. Token scan (mg/mcg/g/AUC/m2/Gy/cGy/cycle/day/week/q-schedule) returned no matches.
"WHO grade 1", "grade I-II", "BRAF V600E" are grade/mutation nomenclature, not doses. The
"What was deliberately omitted" section correctly states DeVita's ganglioglioma dose/outcome
figures were excluded rather than misattributed.

## 4. Scope
Appropriately hedged throughout as decision-support. MDT referral, molecular testing, and
escalation triggers are framed as considerations, not mandates.

## 5. Adversarial flags
None to reconcile — no .verdict.md at the sidecar path.

## Critical
None.

## Important
None.

## Advisory
- Optional: the BRAF/MEK targeted-therapy paragraph is correctly labelled general standard; if a
  cited source for CNS BRAF-altered LGG (e.g., NCCN CNS) is available in structured refs, linking it
  would further strengthen grounding. Not blocking.

Confidence: 92.
